Glenmark Pharmaceuticals is currently trading at Rs. 416.25, up by 4.20 points or 1.02% from its previous closing of Rs. 412.05 on the BSE.
The scrip opened at Rs. 412.00 and has touched a high and low of Rs. 417.30 and Rs. 411.65 respectively. So far 15360 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 449.75 on 31-Aug-2012 and a 52 week low of Rs. 265.00 on 21-Dec-2011.
Last one week high and low of the scrip stood at Rs. 440.00 and Rs. 399.00 respectively. The current market cap of the company is Rs. 11195.83 crore.
The promoters holding in the company stood at 48.26% while Institutions and Non-Institutions held 38.90% and 12.84% respectively.
Glenmark Generics Inc., USA a subsidiary of Glenmark Generics has been granted tentative approval for Rizatriptan Benzoate tablets from the United States Food and Drug Administration (USFDA), its generic version of Merck’s Maxalt tablets.
According to IMS Health for the 12 month period ending June 2012, Rizatriptan Benzoate immediate release tablets achieved sales of $ 315 million.
Glenmark’s current portfolio consists of 81 products authorized for distribution in the U.S mark place and 41 ANDA’s pending approval with the U.S. FDA.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1827.00 |
Dr. Reddys Lab | 1373.60 |
Cipla | 1491.70 |
Lupin | 2250.40 |
Zydus Lifesciences | 1009.40 |
View more.. |